• 1
    Smith MA, Gloeckler Reis LA. Childhood cancer: incidence, survival and mortality. In: PizzoPA, PoplackDG, editors. Principles and practice of pediatric oncology. Philadelphia: Lippincott, Williams & Williams; 2002: 1-12.
  • 2
    Bissery M-C, Guenard D, Gueritte-Voegelein F, Lavelle F. Experimental antitumor activity of Taxotere (RP 56976, NSC 628503), a taxol analogue. Cancer Res. 1991; 51: 4845-4852.
  • 3
    Ringel I, Horwitz SB. Studies with RP 56976 (Taxotere®): a semisynthetic analogue of taxol. J Natl Cancer Inst. 1991; 83: 288-291.
  • 4
    Ganansia-Leymarie V, Bischoff P, Bergerat JP, Holl V. Signal transduction pathways of taxanes-induced apoptosis. Curr Med Chem Anticancer Agents. 2003; 3: 291-306.
  • 5
    Blaney SM, Seibel NL, O'Brien M, et al. Phase I trial of docetaxel administered as a 1-hour infusion in children with refractory solid tumors: a collaborative Pediatric Oncology Branch, National Cancer Institute and Children's Cancer Group trial. J Clin Oncol. 1997; 15: 1538-1543.
  • 6
    Seibel NL, Blaney SM, O'Brien M, et al. Phase I trial of docetaxel with filgrastim support in pediatric patients with refractory solid tumors: a collaborative Pediatric Oncology Branch, National Cancer Institute and Children's Cancer Group trial. Clin Cancer Res. 1999; 5: 733-737.
  • 7
    Tomiak E, Piccart MJ, Kerger J, et al. Phase I study of docetaxel as a 1-hour intravenous infusion on a weekly basis. J Clin Oncol. 1994; 12: 1458-1467.
  • 8
    Mitchell PL, Basser R, Chipman M, et al. A Phase I dose-escalation of docetaxel with granulocyte colony-stimulating factor in patients with solid tumours. Ann Oncol. 2003; 14: 788-794.
  • 9
    Masters GA, Brockstein BE, Mani S, et al. Phase 1 dose escalation study of docetaxel with filgrastim support in patients with advanced solid tumors. Med Oncol. 2003; 20: 7-12.
  • 10
    Nistico C, Cognetti F, Frontini L, et al. Weekly docetaxel in pretreated metastatic breast cancer patients: a Phase I-II study. Oncology. 2005; 68: 356-363.
  • 11
    Oken MM, Creech RH, Tormey DC, et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol. 1982; 5: 649-655.
  • 12
    National Cancer Institute. Guidelines for reporting of adverse drug reactions. Bethesda, MD: Division of Cancer Treatment, National Cancer Institute; 1988.
  • 13
    Kalbfleisch JD, Prentice RL. The statistical analysis of failure time data. New York: John Wiley & Sons; 1980.
  • 14
    Liang K, Zeger SL. Longitudinal data analysis using generalized linear models. Biometrika. 1986; 73: 13-22.
  • 15
    Strissel Broeker PL, Super HG, Thirman MJ, et al. Distribution of 11q23 Breakpoints within the MLL breakpoint cluster region in de novo acute leukemia and in treatment-related acute myeloid leukemia: correlation with scaffold attachment regions and topoisomerase II consensus binding sites. Blood. 1996; 87: 1912-1922.
  • 16
    Mollinedo F, Gajate C. Microtubules, microtubule-interfering agents and apoptosis. Apoptosis. 2003; 8: 413-450.
  • 17
    Kraus LA, Samuel SK, Schmid SM, Dykes DJ, Waud WR, Bissery MC. The mechanism of action of docetaxel (Taxotere) in xenograft models is not limited to bcl-2 phosphorylation. Invest New Drugs. 2003; 21: 259-268.
  • 18
    Stein CA. Mechanisms of action of taxanes in prostate cancer. Semin Oncol. 1999; 26: 3-7.
  • 19
    Rowinsky EK, Onetto N, Canetta RM, Arbuck SG. Taxol: the first of the taxanes, an important new class of antitumor agents. Semin Oncol. 1992; 19: 646-662.
  • 20
    van Zuylen L, Verweij J, Nooter K, Brouwer E, Stoter G, Sparreboom A. Role of intestinal P-glycoprotein in the plasma and fecal disposition of docetaxel in humans. Clin Cancer Res. 2000; 6: 2598-2603.
  • 21
    Markman M. Managing taxane toxicities. Support Care Cancer. 2003; 11: 144-147.
  • 22
    Bronstad A, Berg A, Reed RK. Effects of the taxanes paclitaxel and docetaxel on edema formation and interstitial fluid pressure. Am J Physiol Heart Circ Physiol. 2004; 287: H963H968.
  • 23
    Hensley ML, Maki R, Venkatraman E, et al. Gemcitabine and docetaxel in patients with unresectable leiomyosarcoma: results of a Phase II trial. J Clin Oncol. 2002; 20: 2824-2831.
  • 24
    Dumez H, Louwerens M, Pawinsky A, et al. The impact of drug administration sequence and pharmacokinetic interaction in a Phase I study of the combination of docetaxel and gemcitabine in patients with advanced tumors. Anticancer Drugs. 2002; 13: 583-593.
  • 25
    Bhargava P, Marshall JL, Fried K, et al. Phase I and pharmacokinetic study of two sequences of gemcitabine and docetaxel administered weekly to patients with advanced cancer. Cancer Chemother Pharmacol. 2001; 48: 95-103.
  • 26
    Engels FK, Verweij J. Docetaxel administration schedule: From fever to tears? A review of randomized studies. Eur J Cancer. 2005; 41: 1117-1126.